Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

Next Previous
X
Search
Trial Profile

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risuteganib (Primary)
  • Indications Macular degeneration
  • Focus Therapeutic Use
  • Sponsors Allegro Ophthalmics

    • Most Recent Events

    • 13 Jul 2015 Primary endpoint has been met. (Release of Vitreo Macular Adhesion (VMA) by Optical Coherence Tomography (OCT)), as reported by an Allegro Ophthalmics media release.
    • 13 Jul 2015 Top-line results published in the Allegro Ophthalmics Media Release.
    • 23 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top